{"id":"1c328645-260b-5570-adb1-3515a650bf05","stable_key":"8c946991-97f0-55ee-8df0-00e67621962f:nad-plus-oral-formulation-clinical-null","predicate":"has_no_multiplicity_adjusted_benefit","statement":"No secondary clinical, vital-sign, wellbeing or wearable-derived endpoint survived multiplicity correction in the LNAD+ trial; one mild nausea event occurred in the active arm.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"e839f431-e525-5828-bde1-a43dcf870200","mechanism_event_label":"A large biomarker change did not establish a clinical benefit.","subject":{"id":"9cf73903-df6e-575d-aec2-9a3c67e2054a","slug":"lnad-plus-formulation","display_name":"LathMized NAD+ formulation","entity_type_key":"chemical_species"},"object":{"id":"3e2ae5a2-201f-5a1a-bf3a-ad4c31b1289c","slug":"human-lnad-short-term-clinical-endpoints","display_name":"Short-term clinical endpoints in the LNAD trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e839f431-e525-5828-bde1-a43dcf870200","stable_key":"8c946991-97f0-55ee-8df0-00e67621962f:nad-plus-oral-formulation-clinical-null-event","event_type":"observed_relationship","label":"A large biomarker change did not establish a clinical benefit.","description":"No secondary clinical, vital-sign, wellbeing or wearable-derived endpoint survived multiplicity correction in the LNAD+ trial; one mild nausea event occurred in the active arm.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9cf73903-df6e-575d-aec2-9a3c67e2054a","slug":"lnad-plus-formulation","display_name":"LathMized NAD+ formulation","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"3e2ae5a2-201f-5a1a-bf3a-ad4c31b1289c","slug":"human-lnad-short-term-clinical-endpoints","display_name":"Short-term clinical endpoints in the LNAD trial","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"283ed24b-06a1-50aa-9281-df3bac6ce37e","slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Same short trial; exploratory secondary outcomes.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Five days cannot establish long-term safety, longevity or disease prevention. Retrospective registration and industry-affiliated authors remain visible in the reference record.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"nad-plus","display_name":"NAD+","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A large biomarker change did not establish a clinical benefit.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"67112fcb-2e3b-5359-8498-c7736e7bc21a","evidence_kind":"source_excerpt","locator":"Lines 324-330","start_line":324,"end_line":330,"excerpt":"## nad-plus-oral-formulation-clinical-null\nA large biomarker change did not establish a clinical benefit.\nNo secondary clinical, vital-sign, wellbeing or wearable-derived endpoint survived multiplicity correction in the LNAD+ trial; one mild nausea event occurred in the active arm.\nModel: Same short trial; exploratory secondary outcomes.\nLimitations: Five days cannot establish long-term safety, longevity or disease prevention. Retrospective registration and industry-affiliated authors remain visible in the reference record.\nEvidence access: Primary abstract\nOral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1","model_system":"Same short trial; exploratory secondary outcomes.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"f59aa302-d463-5462-876f-e21e64861eac","stable_key":"import-8c946991-97f0-55ee-8df0-00e67621962f","title":"NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"9f5324d0d652c80ad630b3100e28ce34cd2ce260ea2e1324332a4262ce72ae09","revision_id":"0e07909c-e8bc-5950-bafc-61371d9d6412","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}